Histogenetic subclassification of lymphomas in HIV-infected individuals and clinical outcome reported in the current literature in cART era
Histotype . | GC . | Post-GC . | ||||
---|---|---|---|---|---|---|
GC B-cell type . | Activated B-cell type . | Plasmablastic type/plasma cell type . | ||||
BL . | DLBCL-CB . | DLBCL-IB . | PBL . | PEL . | KSHV + MCD . | |
Phenotypic features | ||||||
CD10 | + | + | −/+ | −/+ | − | − |
BCL-6 | + | + | − | − | − | − |
MUM1 | − | − | + | + | + | + |
CD138 | − | − | −/+ | +/− | + | +/− |
Immunodeficiency | From mild————————————————————————————————–→ to severe | |||||
Outcome | Improved outcome in cART era | Improved outcome in cART era | Improved outcome in cART era | Poor prognosis | Poor prognosis | Poor prognosis |
Histotype . | GC . | Post-GC . | ||||
---|---|---|---|---|---|---|
GC B-cell type . | Activated B-cell type . | Plasmablastic type/plasma cell type . | ||||
BL . | DLBCL-CB . | DLBCL-IB . | PBL . | PEL . | KSHV + MCD . | |
Phenotypic features | ||||||
CD10 | + | + | −/+ | −/+ | − | − |
BCL-6 | + | + | − | − | − | − |
MUM1 | − | − | + | + | + | + |
CD138 | − | − | −/+ | +/− | + | +/− |
Immunodeficiency | From mild————————————————————————————————–→ to severe | |||||
Outcome | Improved outcome in cART era | Improved outcome in cART era | Improved outcome in cART era | Poor prognosis | Poor prognosis | Poor prognosis |
Histogenetic lymphomas subclassification27,28; reported clinical outcomes.27,28 BL, Burkitt lymphoma; DLBCL-CB, diffuse large B-cell lymphoma, centroblastic variant; DLBCL-IB, diffuse large B-cell lymphoma, immunoblastic variant; PBL, plasmablastic lymphoma; PEL, primary effusion lymphoma; –, absent; +, present; +/− usually present; −/+, usually absent.